Merus BV (MRUS)
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- 90.000
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- 97.140
- Volume Ratio
- 0.00
- Turnover Ratio
- --
Merus BV Analyst Rating
View moreForecast & Rating
Dec 15, 2025Price forecast
--100.00%
Forecast & RatingHold
15analysts
- Strong buy13.33%
- Buy0.00%
- Hold86.67%
- Sell0.00%
- Strong sell0.00%
News
- Tip Ranks · Feb 20 at 04:59 PM
Morning News Wrap-Up: Friday's Biggest Stock Market Stories!
- Unusual Whales · Feb 20 at 01:03 PM
Zenocutuzumab treatment shows continued benefit in NRG1+ NSCLC patients beyond progression: eNRGy trial results.
- prnewswire · Feb 17 at 05:42 PM
12:39 ETMerus Advances RiverGate Redevelopment Plans, Detailing Scope and Approximately $450 Million Investment
- Top Gainers&Losers · Dec 29, 2025 at 10:01 PM
Top 10 US Stock Losers (12.29)
- Market Beat · Dec 26, 2025 at 09:31 PM
Stock Traders Buy High Volume of Call Options on Merus (NASDAQ:MRUS)
